-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the hair loss therapy developer "Stemson Therapeutics" received US$15 million in Series A financing
The company has done such a survey, as shown below:
Not only in the United States, but in the world, thousands of men and women suffer from all kinds of hair loss every year, including the hair loss itself and the trauma caused by it
In 2018, "Stemson Therapeutics" in San Diego, California, was founded and led by CEO Geoff Hamilton and Chief Scientific Officer Dr.
This investment is led by DCVC Bio, followed by Genoa Ventures, AbbVie Ventures and other investors to support Stemson's research on restoring human hair growth through a new cell regeneration technology that uses patients’ own cells to generate new hair follicles, in order to advance Stemson’s proprietary treatment of hair loss Development of treatment options
DCVC Bio Co-Managing Partner Dr.
After the A round of financing, the company raised a total of 22.
"Almost 30 years have passed since the last hair loss treatment approved by the FDA, but millions of people still suffer physical and mental effects from hair loss each year," said Dr.
"We are very happy and honored to welcome DCVC Bio and a group of outstanding investors to join the Stemson team.
By 2028, the hair restoration market is expected to exceed USD 13.
